Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer

Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer

This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).

Inclusion Criteria:

• Postmenopausal women
• Diagnosed with hormone-receptor positive breast cancer
• Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole
• Good command of the English language
• Under the care of a medical oncologist at Princess Margaret Hospital

Exclusion Criteria:

• Previously received chemotherapy
• Recurrent and/or metastatic disease
• History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)